Kikkawa Naoko, Kinoshita Takashi, Nohata Nijiro, Hanazawa Toyoyuki, Yamamoto Noriko, Fukumoto Ichiro, Chiyomaru Takeshi, Enokida Hideki, Nakagawa Masayuki, Okamoto Yoshitaka, Seki Naohiko
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Int J Oncol. 2014 Jun;44(6):2085-92. doi: 10.3892/ijo.2014.2349. Epub 2014 Mar 19.
Our recent study of the microRNA (miRNA) expression signature of hypopharyngeal squamous cell carcinoma (HSCC) revealed that microRNA-504 (miR-504) is significantly downregulated in HSCC tissues, suggesting that this miRNA is a candidate tumor suppressor. However, several previous reports indicated that miR-504 has an oncogenic function through targeting TP53. The aim of this study was to investigate the functional significance of miR-504 in cancer cells and to identify novel targets regulated by this miRNA in HSCC cells. First, we confirmed the downregulation of miR-504 in HSCC clinical specimens (P<0.0001) by qPCR. Using two sources of miR-504 to restore function, we observed significant inhibition of cancer cell proliferation in head and neck SCC (HNSCC) cell lines (FaDu, SAS and HSC3) and HCT116 colon carcinoma cells (p53+/+ and p53-/-). In HNSCC cells, induction of cell cycle arrest was observed by miR-504 transfection. To identify the molecular targets of miR-504, we performed gene expression analysis of miR-504 transfectants and in silico database analyses. Our data showed that cell cycle-related genes (RB1, CDK6, CDC23 and CCND1) were candidate target genes of miR-504. In HSCC clinical specimens, the expression of cyclin-dependent kinase 6 (CDK6) was significantly higher in cancer tissues compared to non-cancer tissues (P=0.0004). A significant inverse correlation between CDK6 and miR-504 expression was found (r=-0.43, P=0.0039). Expression of miR-504 inhibited CDK6 expression in HNSCC cells. Loss of tumor-suppressive miR-504 enhanced HSCC cell proliferation through targeting CDK6. The identification of novel tumor-suppressive miR-504-mediated molecular pathways and targets provide new insights into HSCC oncogenesis.
我们最近对下咽鳞状细胞癌(HSCC)的微小RNA(miRNA)表达特征进行的研究表明,微小RNA - 504(miR - 504)在下咽鳞状细胞癌组织中显著下调,这表明该miRNA是一种候选肿瘤抑制因子。然而,先前的一些报道指出,miR - 504通过靶向TP53具有致癌功能。本研究的目的是探讨miR - 504在癌细胞中的功能意义,并确定该miRNA在HSCC细胞中调控的新靶点。首先,我们通过定量聚合酶链反应(qPCR)证实了miR - 504在下咽鳞状细胞癌临床标本中的下调(P<0.0001)。使用两种来源的miR - 504来恢复其功能,我们观察到头颈部鳞状细胞癌(HNSCC)细胞系(FaDu、SAS和HSC3)以及HCT116结肠癌细胞(p53+/+和p53-/-)的癌细胞增殖受到显著抑制。在HNSCC细胞中,通过转染miR - 504观察到细胞周期停滞的诱导。为了确定miR - 504的分子靶点,我们对miR - 504转染细胞进行了基因表达分析,并进行了计算机数据库分析。我们的数据表明,细胞周期相关基因(RB1、CDK6、CDC23和CCND1)是miR - 504的候选靶基因。在下咽鳞状细胞癌临床标本中,与非癌组织相比,细胞周期蛋白依赖性激酶6(CDK6)在癌组织中的表达显著更高(P = 0.0004)。发现CDK6与miR - 504表达之间存在显著的负相关(r = -0.43,P = 0.0039)。miR - 504的表达抑制了HNSCC细胞中CDK6的表达。肿瘤抑制性miR - 504的缺失通过靶向CDK6增强了下咽鳞状细胞癌细胞的增殖。对新的肿瘤抑制性miR - 504介导的分子途径和靶点进行鉴定,为下咽鳞状细胞癌的肿瘤发生提供了新的见解。